Clinical trials: Bladder Tumors
Superficial Bladder Cancer, Lower Urinary Tract Symptoms
Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms
Baobab oil is often used in traditional medicine as antipyretic, antioxidant, anti-inflammatory, analgesic and antimicrobial. It also regenerates the epithelial tissue in a short time improving tone and elasticity.
- Trial name
- Baobab (NCT01939756)
- Testing
- Intravesical baobab oil
- Where
- 2 sites in Italy
- Volunteers
- 50 people
- Sponsor
- Savino M. Di Stasi
Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
The study designed is to evaluate the safety of Canady Helios™ Cold Plasma Scalpel (CHCPS) in patients with solid tumors with carcinomatosis scheduled to undergo surgical resection for cytoreduction.
- Conditions
- Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer, Stage IV Prostate Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT04267575
- Testing
- Canady Helios Cold Plasma Scalpel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jerome Canady, M.D.
Muscle Invasive Bladder Cancer (MIBC)
Vedisertib (RC48/ADC) Combined With Toripalimab in Bladder-preserving Treatment
This is a phase II clinical study to evaluate the efficacy of RC48-ADC combined with toripalimab bladder-sparing therapy. The RC48-ADC dose in this study is 2.0 mg/kg Q2W and toripalimab is 3 mg/kg Q2W.
- Trial name
- NCT07201675
- Testing
- RC48-ADC combined with toripalimab for bladder-sparing therapy
- Volunteers
- 59 people
- Sponsor
- Qilu Hospital of Shandong University
Bladder Cancer, LUTS
Protoves M1® Syrup in Controlling Adverse Event During HIVEC® Instillations
100 patients with bladder cancer whose underwent Hyperthermic Intravesical Chemotherapy (HIVEC®) will be randomized in two groups (Group A: PROTOVES M1 SYRUP, Group B: NO TREATMENT).
- Conditions
- Bladder Cancer, LUTS, Pain
- Trial name
- NCT04148677
- Testing
- Protoves M1®
- Volunteers
- 100 people
- Sponsor
- Cardarelli Hospital
Bladder Cancer
The Efficacy of Gallium[68Ga]NOTA-DNA Multivalent SGC8 Injection for Bladder Tumour Imaging
The study was planned to include patients with bladder tumors attending the Department of Urology, Renji Hospital, Shanghai Jiaotong University School of Medicine, from 09/2024 to 12/2025.
- Trial name
- NCT06763354
- Testing
- Gallium[68Ga]NOTA-DNA Multivalent SGC8 Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- RenJi Hospital
Bladder Cancer
MRI in Clinical Staging and Estimation of Treatment Response in Bladder Cancer
Bladder cancer (BC) as the most common malignancy arising from the urinary tract continues to be a major health problem. This prospective non-randomized study will enroll 150 patients undergoing magnetic resonance imaging (MRI)…
- Trial name
- MIB (NCT02662166)
- Testing
- MR imaging
- Where
- 2 sites in Finland
- Volunteers
- 50 people
- Sponsor
- Turku University Hospital
Non-muscle Invasive Bladder Cancer
Study of CG0070 After Transurethral Resection in Patients With IR NMIBC
Investigators will evaluate the safety of CG0070 for the treatment of patients with Intermediate-Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC).
- Trial name
- NCT06253845
- Testing
- CG0070
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-Muscle Invasive Bladder Carcinoma
Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer
This phase IV trial studies whether there is a relationship between how a patient is positioned while receiving bacillus Calmette Guerin (BCG) within the bladder (intravesical) and how long BCG stays in the bladder (dwell time)…
- Trial name
- NCT07474519
- Testing
- Accelerometry, BCG Solution, Electronic Health Record Review
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Non-muscle Invasive Bladder Cancer
A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
The study aims to establish the safety, tolerability, pharmacokinetics (PK), relevant biomarkers, pharmacodynamics (PD) and preliminary anti-tumor activity of the intravesical administration of eciskafusp alfa in combination with…
- Trial name
- NCT06816017
- Testing
- Eciskafusp Alfa, BCG Medac Strain
- Where
- 9 sites in Australia, Italy and 4 more
- Sponsor
- Hoffmann-La Roche
Invasive Bladder Cancer, Bladder Cancer
Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin
The standard treatment of muscle invasive bladder cancer is to administer chemotherapy for approximately 3 months then to have surgery to remove the bladder.
- Trial name
- NCT02030574
- Testing
- Gemcitabine and fractionated cisplatin (combination treatment)
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Brown University
Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
The main purpose of this study is to evaluate the safety and preliminary efficacy of the combination of the study drug known as ramucirumab plus pembrolizumab in participants with locally advanced and unresectable or metastatic…
- Conditions
- Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell
- Trial name
- NCT02443324
- Testing
- Ramucirumab, Pembrolizumab
- Where
- 22 sites in United States, France and 4 more
- Volunteers
- 175 people
- Sponsor
- Eli Lilly and Company
Urinary Bladder Neoplasms
CIK in Treating Patients With Bladder Cancer
Chemotherapy is the main treatment method for patients with Bladder Cancer. However, Relapse remains the major cause of treatment failure.Biological therapies such as CIK stimulate the immune system and stop tumor cells from…
- Trial name
- NCT02489890
- Testing
- Cytokine-induced Killer Cells
- Volunteers
- 1,500 people
- Sponsor
- The First People's Hospital of Changzhou
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00792025
- Testing
- sunitinib malate
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- Institut Curie
Bladder Cancer, Bladder
A Window of Opportunity Phase I Study of UGN-201 in Patients With Bladder Cancer Undergoing Radical Cystectomy Protocol #: 2021-0630
he primary objective is to characterize the safety profile of UGN-201 in patients with urothelial carcinoma undergoing radical cystectomy.
- Trial name
- NCT05055050
- Testing
- UGN-201
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
HER2-positive Breast Cancer, HER2-positive Gastric Cancer
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
A Phase 1b, open-label, dose escalation study of PRS-343 in combination with atezolizumab in patients with HER2-positive advanced or metastatic solid tumors.
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Bladder Cancer, HER2-positive Solid Tumor
- Trial name
- NCT03650348
- Testing
- PRS-343 in Combination with Atezolizumab
- Where
- 8 sites in United States
- Volunteers
- 41 people
- Sponsor
- Pieris Pharmaceuticals, Inc.
Prostate Cancer
Cystoprostatectomy Versus Radiotherapy Combined With ADT for the Treatment of cT4 Prostate Cancer With Bladder Invasion
Prostate cancer is the most common male cancer in global, which accounts for 19% of the total and poses great hazards to male health.
- Trial name
- CRADT (NCT03482089)
- Testing
- Cystoprostatectomy, external beam radiotherapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Tongji Hospital
Bladder Cancer
Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer
Study participants will have been diagnosed with bladder cancer that has invaded the muscle wall of the bladder. Surgery is used to remove cancer when it is in the muscle of the bladder.
- Trial name
- NCT00585689
- Testing
- ABI-007, Carboplatin, Gemcitabine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Michigan Rogel Cancer Center
Bladder Cancer, Cervical Cancer
Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer
RATIONALE: Radiation therapy can cause long-term adverse effects. Hyperbaric oxygen therapy may be effective in lessening gastrointestinal symptoms caused by radiation therapy given for pelvic cancer.
- Conditions
- Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer
- Trial name
- NCT01087268
- Testing
- questionnaire administration, gastrointestinal complications management/prevention, quality-of-life assessment
- Where
- United Kingdom
- Volunteers
- 75 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostate Cancer, Bladder Cancer
Feasibility Study of Urinary cfDNA Analysis as a Non-invasive Monitoring Tool in Patients With Prostate or Bladder Cancer
The UroDNA study is a feasibility study (RIPH category 3) aimed at evaluating the analysis of circulating tumour DNA in urine (urinary cfDNA) as a non-invasive monitoring tool in patients with prostate or bladder cancer.
- Trial name
- UroDNA (NCT07468838)
- Volunteers
- 25 people
- Sponsor
- Institut Cancerologie de l'Ouest
Cancer, Metastasis Lung
Relationship Between Circulating Tumor Cell Cultures' Treatment Response and Clinical Outcomes
The purpose of this prospective, non-randomized, single-center pilot exploratory study is to investigate whether established circulating tumor cell (CTC) cultures have a similar response to targeted therapy treatment as the in…
- Conditions
- Cancer, Metastasis Lung, Metastasis to Liver, Circulating Tumor Cell
- Trial name
- NCT04280640
- Testing
- Blood Draw
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.